Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 12, pp. 1113-1124
Open Access | Times Cited: 1337

Showing 1-25 of 1337 citing articles:

Non-alcoholic fatty liver disease
Elizabeth E. Powell, Vincent Wai–Sun Wong, Mary E. Rinella
The Lancet (2021) Vol. 397, Iss. 10290, pp. 2212-2224
Closed Access | Times Cited: 1878
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, et al.
Hepatology (2023) Vol. 77, Iss. 5, pp. 1797-1835
Open Access | Times Cited: 1191
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1176
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1925-1966
Open Access | Times Cited: 680
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 669
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 9, pp. 599-612
Closed Access | Times Cited: 586
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven Francque, Pierre Bédossa, Vlad Ratziu, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 17, pp. 1547-1558
Open Access | Times Cited: 487
A global view of the interplay between non-alcoholic fatty liver disease and diabetes
Norbert Stefan, Kenneth Cusi
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 4, pp. 284-296
Closed Access | Times Cited: 402
Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association
P. Barton Duell, Francine K. Welty, Michael Miller, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2022) Vol. 42, Iss. 6
Open Access | Times Cited: 397
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Emily Brown, Hiddo J.L. Heerspink, Daniel J. Cuthbertson, et al.
The Lancet (2021) Vol. 398, Iss. 10296, pp. 262-276
Open Access | Times Cited: 391
Immune cell-mediated features of non-alcoholic steatohepatitis
Thierry Huby, Emmanuel L. Gautier
Nature reviews. Immunology (2021) Vol. 22, Iss. 7, pp. 429-443
Open Access | Times Cited: 391
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
Fasiha Kanwal, Jay H. Shubrook, Leon A. Adams, et al.
Gastroenterology (2021) Vol. 161, Iss. 5, pp. 1657-1669
Open Access | Times Cited: 378
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach
Giovanni Targher, Herbert Tilg, Christopher D. Byrne
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 7, pp. 578-588
Open Access | Times Cited: 377
Gut-liver axis: Pathophysiological concepts and clinical implications
Herbert Tilg, Timon E. Adolph, Michael Trauner
Cell Metabolism (2022) Vol. 34, Iss. 11, pp. 1700-1718
Open Access | Times Cited: 371
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Daniel Ferguson, Brian N. Finck
Nature Reviews Endocrinology (2021) Vol. 17, Iss. 8, pp. 484-495
Open Access | Times Cited: 340
Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States
Donghee Kim, Peter Konyn, Keeryth K. Sandhu, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 6, pp. 1284-1291
Closed Access | Times Cited: 333
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai–Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 332
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Lawrence Blonde, Guillermo E. Umpierrez, Sarah Reddy, et al.
Endocrine Practice (2022) Vol. 28, Iss. 10, pp. 923-1049
Open Access | Times Cited: 327
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Herbert Tilg, Timon E. Adolph, Michael Dudek, et al.
Nature Metabolism (2021) Vol. 3, Iss. 12, pp. 1596-1607
Closed Access | Times Cited: 305
GLP-1 physiology informs the pharmacotherapy of obesity
Daniel J. Drucker
Molecular Metabolism (2021) Vol. 57, pp. 101351-101351
Open Access | Times Cited: 281
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
Wah‐Kheong Chan, Kee Huat Chuah, Ruveena Bhavani Rajaram, et al.
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 3, pp. 197-213
Open Access | Times Cited: 281
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Marlene Chakhtoura, Rachelle Haber, Malak Ghezzawi, et al.
EClinicalMedicine (2023) Vol. 58, pp. 101882-101882
Open Access | Times Cited: 273
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Xin Zhao, Minghe Wang, Zhitong Wen, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 256
NAFLD: Mechanisms, Treatments, and Biomarkers
Fatiha Nassir
Biomolecules (2022) Vol. 12, Iss. 6, pp. 824-824
Open Access | Times Cited: 254
Targeting fibrosis: mechanisms and clinical trials
Manyu Zhao, Liqun Wang, Mengzhu Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 253
Page 1 - Next Page

Scroll to top